anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
262,080. Rõth, C. Nov. 24. 1925, [Convention date]. Vaccines and immunizing and like serums; bacteria, cultivating; medicines for internal use.- Chemical compounds of the pyridine or quinoline series capable of influencing the causative microorganisms of disease, as described in Specification 247,965, are caused to act in vitro on cultures of spirochaetae, trypanosomes, cocci, or the like instead of being injected into an animal in conjunction with the micro-organisms. Cultures may be treated with the chemicals or the organisms may be grown on media containing the chemicals. The treated organisms become non- virulent, and if necessary may be further weakened by other means such as heating. The preparations may be used directly for immunizing or curative treatment, or may be injected into an animal, either alone, or in combination with chemicals of the kind described, or with other attenuated or virulent cultures, for the production of immunizing materials which are recovered from the organs or blood of the animal. According to one example, nutrient broth containing a small proportion of the sodium salt of 2-oxy-5- iodopyridine is inoculated with a virulent culture of streptococci and allowed to stand, or the iodopyridine compound may be added 24 hours after inoculation of the nutrient fluid with the virulent culture. According to a second example, washed and centrifuged gonococci are suspended in salt solution and a solution of the iodopyridine compound is then added. The Specification as open to inspection under Sect. 91 (3) (a) relates also to the use, in connection with the present invention or with that of the Specification 247,965, of substances having structural or biological relationships with albumen or its fission products, or capable of developing substances having these properties in the animal organism. This subject-matter does not appear in the Specification as accepted.
PURPOSE:To pulverize a drug or drug composition having poor heat-stability easily without lowering the activity of the drug, by pulverizing the drug, etc., under cooling. CONSTITUTION:A drug or drug composition having poor heat-stability (e.g. PG, prostacyclin, growth hormone releasing factor, interferon, etc.) is pulverized under cooling. The drug composition is preferably a composite of the drug with a bio-degradable carrier such as collagen, gelatin, polyglycolic acid, etc. The pulverization process comprises the cooling step to cool the specimen to be pulverized and the pulverization chamber before pulverization and the pulverization step to carry out the pulverization of the drug, etc., under cooling. The cooling can be performed e.g. by mixing with a refrigerant such as dry ice, exposing to evaporated cold gas produced from dry ice, liquid nitrogen, etc., or immersing in a refrigerant such as liquid nitrogen. A finely pulverized product can be produced without causing the denaturation of the active component.
Nepal has a health care system that is complicated by access, affordability, and availability. The geographical difficulty makes the health care reach to public more difficult. Nepal being a disasterprone country, it makes very important to strengthen the disaster preparedness up to the mark before the disaster strikes. During disaster and public health emergencies, the healthcare system quickly becomes overwhelmed or structural damage makes it non-functional, which necessitate the prior identification of Alternate Care Site by health service providers. Incorporating the identification of Alternate Care Sites into the Hospital Disaster Preparedness Plan represents a crucial transition from theoretical discussion to practical implementation for strengthening healthcare facilities. . This paper discusses the concept of Alternate Care site and its implementation in Nepal's health emergency preparedness for disaster and public health emergencies.
Dosage must be individualized. For children who can swallow tablets, the usual recommended starting dose of Benicar is 10 mg once daily for patients who weigh 20 to <35 kg (44 to 77 lb), or 20 mg once daily for patients who weigh ≥35 kg. For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to a maximum of 20 mg once daily for patients who weigh <35 kg or 40 mg once daily for patients who weigh ≥35 kg.

Children <1 year of age must not receive Benicar for hypertension.

For children who cannot swallow tablets, the same dose can be given using an extemporaneous suspension as described below [see Clinical Pharmacology (12.3)]. Follow the suspension preparation instructions below to administer Benicar as a suspension.

Preparation of Suspension (for 200 mL of a 2 mg/mL suspension)

Add 50 mL of Purified Water to an amber polyethylene terephthalate (PET) bottle containing twenty Benicar 20 mg tablets and allow to stand for a minimum of 5 minutes. Shake the container for at least 1 minute and allow the suspension to stand for at least 1 minute. Repeat 1-minute shaking and 1-minute standing for four additional times. Add 100 mL of Ora-Sweet®* and 50 mL of Ora-Plus®* to the suspension and shake well for at least 1 minute. The suspension should be refrigerated at 2-8°C (36-46°F) and can be stored for up to 4 weeks. Shake the suspension well before each use and return promptly to the refrigerator.   
* Ora-Sweet® and Ora-Plus® are registered trademarks of Paddock Laboratories, Inc.
The present invention relates to a new purpose of natural plant extracts in the pharmacy field, particularly to the purpose for preparing medicine for treating cerebrovascular diseases. The present invention relates to an application of speedwell extracts in preparing medicine for treating the disease of cerebral apoplexy. The speedwell extracts are speedwell alcohol extracts or water extracts; the speedwell extracts are extractum dry powder or liquid extractum which is obtained by extracting speedwell medicinal materials as raw materials which are heated by water or ethanol. The speedwell extracts have obvious therapeutic effects on rat focal cerebral ischemia, and have protective functions for rat cerebral ischemia reperfusion injury. Additionally, the speedwell extracts have the functions for obviously adding cerebral blood flow (CBF) of an anesthesia dog, reducing CVR, inhibiting platelet aggregation and thrombosis forming, reducing blood viscosity, improving cerebral pia mater microcirculatory disturbance, etc. The speedwell extracts are safe and innocuous.
Patients undergo 18F-FDG PET/CT scan first. Within 7 working days, patients receive 4-\[18F\]Fluoroglutamine IV and 60 minutes after injection, undergo 4-\[18F\]Fluoroglutamine PET/CT before the start of therapy.
All subjects will receive a 15-30 minutes a day treatment for 5 days a week. When the subjects achieves the ability to walk with supervision, but with no physical assistance, safely and consistently during the physiotherapy sessions, then either the FES will be provided to the subject to allow ongoing gait practice with the nursing staff in the ward environment. After discharge, the assistive device will be provided for home usage till the end of the research.
Significant progress has been made in the prevention and treatment of atherosclerosis, but it continues to be a leading cause of morbidity and mortality in our society. The problem will become even more significant as an increasing proportion of the population ages. The goal of the proposed project is to advance our understanding of the genetic mechanisms of atherosclerosis. We propose to identify genes selectively expressed in peripheral monocytes of patients with atherosclerosis and in macrophages and endothelial cells of atherosclerotic plaques. We will examine gene expression profiles in purified subpopulations of cells using Serial Analysis of Gene Expression (SAGE) that requires only minute amounts of RNA, enabling the study of small homogeneous populations of cells. This sequence-based high-throughput gene expression profiling technique has the advantage of not requiring prior knowledge of the expressed gene sequences, allowing the discovery of new genes. With the completion of the human genome sequence, the SAGE technique is an ideal tool for comprehensively characterizing the transcriptomes of the important cells involved in atherosclerosis. This proposal is an exploratory study to find candidates, both known and unknown genes, which will be used for more extensive and statistically powered projects in the future. The insights obtained will be used for elucidating the pathogenesis of atherosclerosis and for developing new simple, sensitive and specific tests for early disease diagnosis. In addition, the new insights obtained may lead to the development of novel therapeutic strategies for disease prevention and treatment.
A sheep-derived low molecular weight heparin, comprising sheep dalteparin sodium, sheep nadroparin calcium, sheep tinzaparin sodium, sheep parnaparin sodium, and sheep bemiparin sodium. The sheep-derived low molecular weight heparin has a common provenance characteristic, and in chemical structure, the content of the main disaccharide ΔUA2S-GlcNS6S(ΔIS) thereof is 66%-74%. The sheep-derived low molecular weight heparin has physical and chemical properties and biological activity similar to those of a pig-derived low molecular weight heparin, so that the source of low molecular weight heparin drugs is expanded. The method for preparing a sheep-derived low molecular weight heparin is simple and easy to implement, and the process is stable. The obtained product is refined and can meet the requirements of pharmacopoeias on the current low molecular weight heparin. The sheep-derived low molecular weight heparin also has the halal property that the pig-derived low molecular weight heparin lacks, has a huge market among Muslim groups, countries and regions, and can be applied in anticoagulant, antithrombotic, antiinflammatory, anticancer and halal drugs.
Therapeutic composites are described for the treatment of a variety of organ related conditions. Any organ or organ system of the body may be treated including the pancreas, kidney, brain, lung, intestine and the like. A therapeutic composition may include a fluid component and a matrix component. A matrix component may be an amniotic membrane and a fluid component may be a fluid having a concentration of amniotic stem cells, and/or micronized amniotic membrane particles. An amniotic stem cell concentrated fluid has at least 0.1 x 10e amniotic stem cells per milliliter of fluid or composition. A therapeutic composition may be used to treat any number of conditions through topical application, injection, or intravenously. A matrix component may be located on a treatment location and a fluid component may subsequently be introduced to the matrix component or the surrounding tissue.
NEAR consists of using carefully selected computer cognitive games to restore cognitive functioning through rehearsal and strategy learning. It will be delivered 3 times a week for 12 weeks at the center. The duration of each session within the week is as follows: 1) First session: 45 min computer-assisted cognitive exercises + 30 min bridging group; 2) Second session: 30 min computer-assisted cognitive exercises + 45 min bridging group; 3) Third session: 45 min computer-assisted cognitive exercises. Computer-assisted cognitive exercises are sessions where participants engage in cognitive games that target different cognitive domains. In addition, the Multicontext Treatment Approach to strategy learning will be carried out. The metacognitive framework of self-evaluation and activity mediation will also be utilized. Bridging groups are conducted twice a week, to aid transfer of learning from the computer game sessions to the participants' everyday life.
Reproductive age women diagnosed with POR based on Bologna criteria with a history of at least two prior failed intracytoplasmic sperm injection (ICSI) cycle will recruited for the study. Antral follicle count (AFC), serum anti-mullerian hormone (AMH), and early follicular phase serum follicle stimulating hormone (FSH) levels will be determined at baseline. Autologous blood obtained from peripheral vein will be used to prepare PRP following standard protocols. PRP injection will be performed under sedation anesthesia, using a 11.8 inch (30 cm) single lumen 21G needles under transvaginal ultrasound guidance. On the 2 to 4th days of the first three menstrual cycles following the procedure, AFC, AMH, and FSH levels will be re-assessed. Patients with at least one antral follicle will be started on ovarian stimulation for ICSI, followed by embryo transfer. Biomarkers of ovarian reserve (AFC, FSH, AMH), and ICSI outcome parameters (number of metaphase II (MII) oocytes, blastocyst embryos, fertilization rate, oocyte and embryo quality) will be followed.
`NMB1870' is a known surface protein in Neisseria meningitidis expressedacross all serogroups. It has three distinct families. Serum raised againsta given family is bactericidal within the same family, but is not active againststrains which express one of the other two families i.e. intra-familybut not inter-family cross-protection. The inventors have found that NMB1870can be divided into domains, and that not all domains are required for antigenicity.Antigenic domains can be taken from each of the three NMB1870 families and expressedas a single polypeptide chain. The inventors have also found that NMB1870 exposessome of its epitopes in surface loops situated between alpha helices, and thatsubstitution of loop epitopes from one family into the loop position in anotherfamily allows chimeric NMB1870 to be produced with multi-family antigenicity.Thus chimeric NMB1870 proteins are provided that comprise portions of NMB1870from different families.
PURPOSE: To obtain a hair conditioning shampoo excellent in combing properties and handleability, containing an alkyl sulfate and/or an alkyl lower alkoxy sulfate instead of another anionic detergent. CONSTITUTION: This objective substance contains 0.5-25wt.% of an anionic detergent which is a 6C, 8C and/or 10C alkyl sulfate and/or a 6C, 8C and/or 10C alkyl lower alkoxy sulfate, 0. 5-10wt.% of a water-insoluble hair conditioning agent (e.g. aminosilicone) and 34-99wt.% of an aqueous medium. The substance can be prepared into a dosage form such as liquid, cream, gel or paste. The substance has pearly luster effects and conditioning characteristics.
Although changes in sexual desire, sexual performance and sexual satisfaction often occur as manifestations of a psychiatric disorder, they may also be a consequence of pharmacologic treatment. In particular, some evidence suggests that selective serotonin reuptake inhibitors (SSRIs) can cause such untoward sexual experiences. Reliable estimates of the incidence and severity of untoward experiences involving sexual desire, performance and satisfaction are difficult to obtain, however, in part because patients and physicians may be reluctant to discuss them. Accordingly, estimates of the incidence of untoward sexual experience and performance cited in product labeling, are likely to underestimate their actual incidence.

Table 5 below displays the incidence of sexual side effects reported by at least 2% of patients taking sertraline in placebo-controlled trials.

There are no adequate and well-controlled studies examining sexual dysfunction with sertraline treatment.

Priapism has been reported with all SSRIs.

While it is difficult to know the precise risk of sexual dysfunction associated with the use of SSRIs, physicians should routinely inquire about such possible side effects.
This is a multi-center clinical study conducted in the USA and two international sites. This open-label, dose escalation study was designed to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered AC220 as a single agent given daily for 14 days. Cohorts of 3 patients received AC220 until dose limiting toxicity was noted (DLT). At that point cohorts expanded to 6 patients until MTD was determined. Patients not experiencing DLT or significant disease progression at Day 15 may have continued receiving AC220 at the discretion of the Investigator and Sponsor. FLT3 positive and negative patients were allowed to participate.
BACKGROUND: Previous studies have indicated a potential link between the gut microbiota and lymphoma. However, the exact causal interplay between the two remains an area of ambiguity.
METHODS: We performed a two-sample Mendelian randomization (MR) analysis to elucidate the causal relationship between gut microbiota and five types of lymphoma. The research drew upon microbiome data from a research project of 14,306 participants and lymphoma data encompassing 324,650 cases. Single-nucleotide polymorphisms were meticulously chosen as instrumental variables according to multiple stringent criteria. Five MR methodologies, including the inverse variance weighted approach, were utilized to assess the direct causal impact between the microbial exposures and lymphoma outcomes. Moreover, sensitivity analyses were carried out to robustly scrutinize and validate the potential presence of heterogeneity and pleiotropy, thereby ensuring the reliability and accuracy.
RESULTS: We discerned 38 potential causal associations linking genetic predispositions within the gut microbiome to the development of lymphoma. A few of the more significant results are as follows: Genus Coprobacter (OR = 0.619, 95% CI 0.438-0.873, P = 0.006) demonstrated a potentially protective effect against Hodgkin's lymphoma (HL). Genus Alistipes (OR = 0.473, 95% CI 0.278-0.807, P = 0.006) was a protective factor for diffuse large B-cell lymphoma. Genus Ruminococcaceae (OR = 0.541, 95% CI 0.341-0.857, P = 0.009) exhibited suggestive protective effects against follicular lymphoma. Genus LachnospiraceaeUCG001 (OR = 0.354, 95% CI 0.198-0.631, P = 0.0004) showed protective properties against T/NK cell lymphoma. The Q test indicated an absence of heterogeneity, and the MR-Egger test did not show significant horizontal polytropy. Furthermore, the leave-one-out analysis failed to identify any SNP that exerted a substantial influence on the overall results.
CONCLUSION: Our study elucidates a definitive causal link between gut microbiota and lymphoma development, pinpointing specific microbial taxa with potential causative roles in lymphomagenesis, as well as identifying probiotic candidates that may impact disease progression, which provide new ideas for possible therapeutic approaches to lymphoma and clues to the pathogenesis of lymphoma.
Damage to the heart caused by a myocardial infarction (heart attack) occurs most often during the early morning hours (6AM). Thus, the involvement of the circadian system (circa= approximately day) has been suggested. The circadian system in humans or animals is based on the rotation of the earth with day and night phases. When humans (or animals) wake up light shines in their eyes and the body receives a signal that the day starts. For the human body it means that certain proteins (named clock, period etc) are produced. The protein that determines the length of a day (awake and sleep period) is called Period 2 (Per2). Recent data indicated that the Per2 protein in hearts from mice is induced after daylight exposure (daylight with an intensity comparable to a bright day at the beach was used, approx. 10 000 LUX). This more Per2 was able to protect the heart from being damaged by no blood going to the heart (protection from a heart attack). This protection was based on a more efficient use of sugars (carbohydrates). Thereby the heart needs less oxygen. Current data indicate that human Per2 is also induced by light exposure and can be detected in human plasma samples.

In this study Per2 transcript and protein levels will be analyzed in patients that just experienced a heart attack with and without intense light (daylight) therapy utilizing blood samples (erythrocytes and leukocytes).
The intervention group will receive access to My Tools for Care - In Care for 2 months. They will also receive a copy of the Alzheimer Society's "The Progression Of Alzheimer's Disease - Overview Booklet".
As with all therapeutic peptides, there is the potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to BAQSIMI with the incidences of antibodies to other products may be misleading.

In 3 clinical trials, 3/124 (2%) of BAQSIMI-treated patients had treatment-emergent anti-drug antibodies as detected by an affinity capture elution (ACE) ligand-binding immunogenicity assay. No neutralizing antibodies were detected.
Fixed formula treatment Group will be given the standard formula Er-Xian decoction consisting of six herbs. The dosages of each herb were standardized according to the latest Chinese Medicine Recipe Dictionary (1997). The standard formula Er-Xian decoction are in the form of water-soluble granules. Each dose contains 11.8g and prepackaged in two identical foil sachets. Participants were instructed to drink one sachet of granules dissolved in 200 mL of warm water twice daily.
A centralized formulary system for maintaining formulary data to service the needs of multiple user groups. Formulary and drug information is updated automatically when received from outside sources. In addition to drug identifying data, line of business and utilization management protocol data is associated with the formulary data. The formulary data further comprises coverage data for health plans that use the formularies. The additional business data maintained in association with the formularies facilitates the retrieval and editing of formulary data for various business needs, including compliance with third party requirements. The system allows users to analyze formulary data, edit formulary data, produce reports regarding formulary data, and export files. The system also supports submission of formulary data to third party computer systems.
They will perform the supervised physical exercise program. The supervised exercise program (ESATRAL) will last 24 weeks with 2-3 non-consecutive weekly sessions. The duration of each session will be 30 minutes and will progressively increase depending on the phase in which we are until reaching 60 minutes.
PURPOSE:To provide a remedy for gray hair, containing at least one compound selected from oxidizing agents and female hormones in an amount to enable the promotion of the activity of tyrosinase, and capable of suppressing the generation of gray hair and promoting the growth of pigment-containing hair. CONSTITUTION:The objective remedy contains at least one compound selected from oxidizing agents (e.g. potassium bromate, sodium bromate, stabilized chlorine dioxide, etc.) and female hormones, as an active component. The amount of the active component is selected to be sufficient to promote the activity of tyrosinase or oxidase which accelerates the formation of melanine in the melanophore of the folliculus pili. The color of the hair is originated from melanine produced by melanocyte, and gray hair occurs when there is no production of melanine. The remedy is effectless when the function of melanocyte is lost, however, the generation of gray hair can be suppressed by using the above oxidizing agent, etc. to promote the activity of the tyrosinase actively to melanocyte in the course of the regeneration of the folliculus pili after the artificial or spontaneous falling of the hair.